Business Context and Reporting Period
This Form 8-K filing by Mink Therapeutics, Inc. (INKT) is dated August 27, 2024. The report addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock price thresholds.
Material Changes
- Delisting Notice: On August 27, 2024, the company received formal notice from Nasdaq stating it failed to regain compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Grace Period Expiration: The 180-calendar day grace period, which began on February 26, 2024, expired on August 26, 2024, without the stock closing above $1.00 per share for the required duration.
- Current Status: The common stock is now subject to potential delisting from Nasdaq.
Outlook, Risks, and Management Commentary
- Management Action: The company intends to request a hearing before the Nasdaq Hearings Panel. This request will stay further delisting action pending the conclusion of the hearing process.
- Trading Status: The stock will continue to be eligible to trade on The Nasdaq Capital Market during the hearing process.
- Risks: There is no assurance that the Panel will determine to continue the listing or that the company can demonstrate compliance within any additional time granted.
Investor Verification Checklist
- Confirm the date and outcome of the hearing request filed with the Nasdaq Hearings Panel.
- Monitor the daily closing bid price of INKT to assess if it meets the $1.00 threshold.
- Review any subsequent filings regarding the Panel's decision on the listing status.
- Verify if the company has announced a reverse stock split or other capital structure changes to regain compliance.